The inclusion of patients finished on December 2016 to the paediatric spironolactone PK study. The aims of the study were:
· To describe the PK profile of spironolactone in children up to 2 years old diagnosed with heart failure, ascites and/or oedema;
· To describe the PK profile of main active metabolism of spironolactone (7-alpha.thiomethylspironolactone, canrenone)
· To correlate the plasma PK profile with the clinical parameters;
· To assess the safety profile of spironolactone.
24 children were included (8 neonates, 6 infants aged 1-6 months, 10 children aged 6 months- 2 years), from whom 201 blood samples were collected.